DODC
DODC is a psychedelic drug from the substituted amphetamine family which acts as an agonist of the 5-HT2A receptor. It is the 3,4-dichloro derivative of the well known psychedelic drug 2,5-Dimethoxy-4-chloroamphetamine (DOC). DODC was first officially published in a patent filed by Gilgamesh Pharmaceuticals in 2020,[1] though anecdotal reports suggest it had been synthesised by clandestine chemists and its activity established several years prior to this.
For the fictional organization, see United States Department of Damage Control.
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C11H15Cl2NO2 |
| Molar mass | 264.15 g·mol−1 |
| 3D model (JSmol) | |
| |
References
- WO 2022/006186, Kruegel AC, "Phenalkylamines and Methods of Treating Mood Disorders.", published January 2022, assigned to Gilgamesh Pharmaceuticals.
| Phenethylamines |
|
|---|---|
| Amphetamines |
|
| Phentermines |
|
| Cathinones |
|
| Phenylisobutylamines | |
| Phenylalkylpyrrolidines | |
| Catecholamines (and close relatives) |
|
| Miscellaneous |
|
| Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.